Abbott's strong cashflow has allowed it to purchase its business and return cash to shareholders through dividends and share repurchases. Abbott includes a long history of returning value to shareholders, and since 2002, the business has delivered $31 billion in cash to its shareholders through dividends and share buybacks. Abbott has elevated its dividend payout for 41 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased their dividend for 25 consecutive years annually.. Abbott’s panel authorizes repurchase of up to $3 billion of common stock Abbott's board of directors has approved a fresh share repurchase plan and declared a quarterly common dividend. Abbott's panel has authorized the repurchase of up to $3 billion of the company's common stock.Yehuda Handelsman, aACE and endocrinologist President. ‘AACE phone calls on Congress to enact this important legislation this year.’ In 2005, osteoporosis was in charge of an estimated two million fractures and $19 billion in costs. By 2025, experts predict that osteoporosis will be responsible for around 3 million fractures and $25.3 billion in costs each year, based on the National Osteoporosis Foundation. AACE commends the Congressional sponsors of the legislation.
Aerovance enrolls 540 sufferers in Stage 2b Aerovant clinical trial Aerovance Inc. Today announced it has completed patient enrollment in a Phase 2b medical trial of the inhaled dry powder formulation of Aerovant for the treating uncontrolled asthma.